Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy, Cancer, vol.86, pp.1216-1246, 1999. ,
Outcome of treatment after fi rst relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial, Leukemia, vol.21, pp.1907-1921, 2007. ,
Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study, Blood, vol.109, pp.944-50, 2007. ,
Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group, Haematologica, vol.95, pp.589-96, 2010. ,
Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation, Blood, vol.120, pp.2032-2073, 2012. ,
Carcinoembryonic antigen as a target for radioimmunotherapy of human medullary thyroid carcinoma: antibody processing, targeting, and experimental therapy with 131 I and 90 Y labeled MAbs, Cancer Biother Radiopharm, vol.14, pp.37-47, 1999. ,
Tumor response to radiotherapy regulated by endothelial cell apoptosis, Science, vol.300, pp.1155-59, 2003. ,
Cancer radioimmunotherapy, Immunotherapy, vol.3, pp.349-70, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-01258870
Radioimmunotherapy for acute leukemia, Cancer Control, vol.9, pp.106-119, 2002. ,
Chemoimmunotherapy in acute lymphoblastic leukemia, Blood Rev, vol.26, pp.25-32, 2012. ,
Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases, Leuk Lymphoma, vol.52, pp.1098-107, 2011. ,
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study, Lancet Oncol, vol.13, pp.403-414, 2012. ,
Antibody fusion proteins anti-CD22 recombinant immunotoxin moxetumomab pasudotox, Clin Cancer Res, vol.17, pp.6398-405, 2011. ,
Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results, Clin Cancer Res, vol.10, pp.5327-5361, 2004. ,
Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diff use large B-cell lymphoma, Blood, vol.118, pp.4053-61, 2011. ,
Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group pilot study, J Clin Oncol, vol.26, pp.3756-62, 2008. ,
SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia, Br J Haematol, vol.165, pp.504-513, 2014. ,
Epratuzumab, a CD22-targeting recombinant humanized antibody with a diff erent mode of action from rituximab, Mol Immunol, vol.44, pp.1331-1372, 2007. ,
High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma, J Clin Oncol, vol.28, pp.3709-3725, 2010. ,
Consolidation anti-CD22 fractionated radioimmunotherapy with 90 Y-epratuzumab tetraxetan following R-CHOP in elderly DLBCL patients: a LYSA phase II prospective trial, Blood, vol.120, p.906, 2012. ,
90 Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma, J Nucl Med, vol.44, pp.77-84, 2003. ,
Comparisons of dosimetric approaches for fractionated radioimmunotherapy of non-Hodgkin lymphoma, Q J Nucl Med Mol Imaging, vol.56, pp.529-566, 2012. ,
Plasma FLT3-L levels predict bone marrow recovery from myelosuprressive therapy, Cancer, vol.88, pp.333-376, 2000. ,
Level of FLT3-ligand in plasma: a possible new bio-indicator for radiation-induced aplasia, Int J Radiat Biol, vol.77, pp.703-715, 2001. ,
BCR-ABL1 molecular remission after 90 Y-epratuzumab tetraxetan radioimmunotherapy in CD22+ Ph+ B-ALL: proof of principle, Eur J Haematol, vol.91, pp.552-56, 2013. ,
Radioimmunotherapy of non-Hodgkin's lymphoma with 90 Y-DOTA humanized anti-CD22 ,
Y-epratuzumab): do tumor targeting and dosimetry predict therapeutic response?, J Nucl Med, vol.44, issue.90, pp.2000-2018, 2003. ,
Normal tissue toxicity after small fi eld hypofractionated stereotactic body radiation, Radiat Oncol, vol.3, p.36, 2008. ,
Lack of CD24 antigen expression in B-lineage acute lymphoblastic leukemia is associated with intrinsic radiation resistance of primary clonogenic blasts, Blood, vol.81, pp.1323-1355, 1993. ,
Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia, Blood, vol.89, pp.2986-93, 1997. ,
Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition, Neoplasia, vol.15, pp.1207-1224, 2013. ,
Radiolabeled antibodies for cancer imaging and therapy, Methods Mol Biol, vol.907, pp.681-97, 2012. ,
90 Yttrium-ibritumomab tiuxetan consolidation of fi rst remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7·3 years from the International, Randomized, Phase III First-Line Indolent trial, J Clin Oncol, vol.31, pp.1977-83, 2013. ,
, , p.22
, Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma, Haematologica, vol.99, pp.1738-1783, 2014.